NextPlat Revenue Declines as Turnaround Efforts Target Profitability
Event summary
- NextPlat Corp. reported $54.3 million in revenue for full-year 2025, an 18% decrease from $66.1 million in the prior year.
- Healthcare Operations revenue fell by $12.6 million to $39.7 million, primarily due to a decline in prescription volume and 340B contract revenue, partially offset by increased reimbursement rates.
- The company cut $2+ million in annualized costs and reduced headcount by over 25% as part of a broader turnaround strategy.
- Gross margin declined to 20% from 26% the previous year, driven by lower 340B contract revenue and increased airtime costs.
The big picture
NextPlat's revenue decline reflects broader challenges in the healthcare sector, including shifts in reimbursement models and increasing pressure on pharmacy margins. The company's turnaround strategy, focused on cost-cutting and higher-margin services, represents a bet on a shift away from traditional retail pharmacy. The success of this strategy will be critical in restoring investor confidence and delivering on the promised value proposition.
What we're watching
- 340B Dependence
- The company's reliance on 340B contract revenue remains a key risk, as changes in reimbursement policies could significantly impact future profitability.
- E-Commerce Growth
- The sustainability of e-commerce revenue growth, particularly from satellite-based connectivity, will depend on maintaining relationships with Globalstar and Iridium and expanding into Latin America.
- Execution Risk
- The company's ability to achieve its projected profitability in 2026 hinges on continued cost reductions and successful execution of its healthcare business development initiatives.
Related topics